Supplements of Fish Oil Outdo
Drug in Heart Study
Associated Press
September 2, 2008; Page D2
MUNICH -- Fish-oil supplements may work slightly better than a popular cholesterol-reducing drug to help patients with chronic heart failure, according to new research. Chronic heart failure is a condition that occurs when the heart becomes enlarged and cannot pump blood efficiently around the body.
The findings could give patients a potential new treatment and could change the dietary recommendations for them, said Jose Gonzalez Juanatey, a spokesman for the European Society of Cardiology, who was not connected to the research. "This reinforces the idea that treating patients with heart failure takes more than just drugs," Dr. Juanatey said.
The study findings were published online in the medical journal The Lancet on Sunday. They were simultaneously announced at a meeting of the European Society of Cardiology in Munich.
Italian researchers gave nearly 3,500 patients a daily omega-3 pill, a prescription-formulation pill derived from fish oils, produced by Norway's Pronova BioPharma. A similar number of patients took placebos. Doctors said people should get the same benefits from taking cheaper options like fish-oil supplements, or just eating more oily fish like salmon.
Roughly the same number of patients were given placebo pills. Patients were followed for an average of four years.
In the group of patients taking the fish-oil pills, 1,981 died of heart failure or were hospitalized with the problem. In the patients on placebo pills, 2,053 died or were hospitalized for heart failure. In a parallel study, the same team of Italian doctors gave 2,285 patients the drug rosuvastatin, also known as Crestor, and gave placebo pills to 2,289 people. Patients were then tracked for about four years as well. The doctors found little difference in heart-failure rates between the two groups.
Comparing the results from both studies, the researchers concluded that fish oil is slightly more effective than the drug because the oil performed better against a placebo than did Crestor. "It's a small benefit, but we should always be emphasizing to patients what they can do in terms of diet that might help," said Richard Bonow, chief of cardiology at Northwestern University Hospital in Chicago and past president of the American Heart Association.
Both studies were paid for by an Italian group of pharmaceutical companies, including Pfizer Inc., Sigma Tau SpA and AstraZeneca PLC.
online.wsj.com |
